News

Public · Published

Guardant Health grants performance-based stock awards to co-CEOs Helmy Eltoukhy and AmirAli Talasaz

Guardant Health granted 465,413 performance-based restricted stock units at target to co-CEOs Helmy Eltoukhy and AmirAli Talasaz. Twenty-five percent is tied to three-year and 75% to five-year relative shareholder returns, with a maximum payout of 250% of target.

Published:

Updated:

What happened

Guardant Health granted 465,413 performance-based restricted stock units at target to co-CEOs Helmy Eltoukhy and AmirAli Talasaz. Twenty-five percent is tied to three-year and 75% to five-year relative shareholder returns, with a maximum payout of 250% of target.

Confirmed

Global impact / market context

Paying leaders mostly in stock that vests only if Guardant beats peers over three and five years ties their reward to long-term shareholder value. If performance lags, the payout falls, which links management's personal gain to investor outcomes rather than fixed salary.

Analyst inference

Investors often track executive pay design because it can influence decisions on spending, hiring and risk. Awards tied to relative shareholder returns, meaning performance compared with other companies, encourage leaders to prioritize durable growth and returns over short-term results that may lift the stock only briefly.

Analyst inference

What to watch

  1. The awards are subject to performance conditions, continued service and post-vesting holding requirements, so the final number of shares earned may differ from the 465,413 target. Confirmed
  2. Whether the company later discloses the peer group used to measure relative shareholder returns, which determines how demanding the performance targets actually are for the co-CEOs. Proposed
  3. Watch future share issuance from these awards, because paying in stock can dilute existing owners if targets are met, while sustained underperformance would reduce the actual payout. Analyst inference

Evidence

  • Original source link unavailable